Concentrix is set to report fourth-quarter results on Jan. 13, 2025, with analysts forecasting earnings of $2.91 per share, down 10.7% from $3.26 in the year-ago period. Revenue is expected at $2.54 billion, marking a 3.7% year-over-year increase from $2.45 billion. The divergence between earnings contraction and top-line growth follows the company’s weaker-than-expected Q3 results and conservative guidance issued in late September.

Among Benzinga’s most accurate analysts, Barrington Research’s Vincent Colicchio and Canaccord Genuity’s Joseph Vafi both upheld Outperform/Buy ratings on Nov. 20 and Sept. 23, respectively, with target prices of $62 and $80. Baird’s David Koning reduced his target from $75 to $62 on Sept. 29, while B of A Securities’ Ruplu Bhattacharya cut his from $65 to $61 on June 27, maintaining a Neutral stance. These analysts possess accuracy rates ranging from 58% to 75%, underscoring measured optimism ahead of the earnings call.

CEO Christopher A. Caldwell acquired 1,000 shares in late October, boosting his stake by 0.35% to 287,661 shares. Over the past 90 days, insiders have bought a total of 4,000 shares. Institutional ownership stands at 90.3%, with AQR Capital Management adding 875,556 shares in Q2 and Arrowstreet Capital increasing its holding by 247.2% to 535,843 shares. New entrants include Deprince Race & Zollo and Norges Bank, indicating broad-based interest from larger asset managers.

MarketBeat data show a consensus “Hold” rating across five brokerages covering Concentrix, with one Sell, one Hold and three Buy recommendations. The average 12-month target among these firms is $66.25, reflecting a moderate upside potential. Weiss Ratings downgraded Concentrix to Sell on Dec. 24, while Wall Street Zen upgraded to Buy on Oct. 25, illustrating contrasting views on the company’s near-term trajectory.